- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07521007
Een fase 2b klinische studie van YN001 bij volwassenen met coronaire atherosclerose (PURIFY-TIMI 81)
Een gerandomiseerde, multicenter, dubbelblinde, parallelle, placebo-gecontroleerde fase 2b klinische studie om de werkzaamheid en veiligheid van YN001 bij volwassenen met coronaire atherosclerose te evalueren
This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a multinational, multicenter, randomized, parallel, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of intravenously administered YN001 compared with placebo in participants with coronary atherosclerosis who are receiving background therapy for CV risk factors management.
A total of 456 participants are expected to be enrolled. The study will consist of a maximum 12-week screening/Baseline period, followed by a 12-week blinded treatment period, a 30-day safety follow-up, and a long-term follow-up period through Week 96 (approximately 2 years after randomization).
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Jingmei Zhang, Master
- Telefoonnummer: 0086 010 82599080
- E-mail: zhangjingmei@innovmedicine.com
Studie Contact Back-up
- Naam: Kaiqi Zong, Master
- Telefoonnummer: 0086 010 82599080
- E-mail: zongkaiqi@innovmedicine.com
Studie Locaties
-
-
New South Wales
-
Penrith, New South Wales, Australië, 2750
- Werving
- Cannopy Clinical Research
-
Contact:
- Karen Kaluhin, MD
- Telefoonnummer: 0061 0491 276 512
- E-mail: kkaluhin@canopycr.com.au
-
-
Queensland
-
Brisbane, Queensland, Australië, 4064
- Werving
- Core Research Group Pty Ltd.
-
Contact:
- David Colquhou, MD
- Telefoonnummer: 614-1184-2788
- E-mail: d.colquhoun@uq.edu.au
-
-
Victoria
-
Altona N., Victoria, Australië, 3025
- Werving
- Canopy Clinical Research
-
Contact:
- Oscar Walsh, MD
- Telefoonnummer: 0061 03 9968 7601
- E-mail: owalsh@canopycr.com.au
-
-
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R2H 2A6
- Nog niet aan het werven
- St. Boniface Hospital
-
Contact:
- Shuangbo Liu
- Telefoonnummer: 204-237-2793
- E-mail: sliu@sbgh.mb.ca
-
-
Ontario
-
London, Ontario, Canada, N5A 5A5
- Nog niet aan het werven
- London Health Sciences Centre
-
Contact:
- Habib Khan
- Telefoonnummer: 519-663-3197
- E-mail: habib.khan@lhsc.on.ca
-
North York, Ontario, Canada, M6B 3H7
- Nog niet aan het werven
- North York Diagnostic and Cardiac Centre
-
Contact:
- Subodh Verma, MD
- Telefoonnummer: 416-436-0244
- E-mail: subodh.verma@unityhealth.to
-
Toronto, Ontario, Canada, M5B 1W8
- Nog niet aan het werven
- St. Michael's Hospital
-
Contact:
- John Graham
- Telefoonnummer: 416-864-6060
- E-mail: John.Graham@unityhealth.to
-
Vaughan, Ontario, Canada, L6A 4N9
- Nog niet aan het werven
- Cardiac Clinic
-
Contact:
- Navneet Singh
- Telefoonnummer: 905-417-3001
- E-mail: navneet.singh@thp.ca
-
-
Toronto
-
Toronto, Toronto, Canada, M5G 2N2
- Nog niet aan het werven
- Toronto General Hospital - University Health Network
-
Contact:
- Jacob Udell
- Telefoonnummer: 416-340-4800
- E-mail: jay.udell@utoronto.ca
-
-
-
-
An
-
Hefei, An, China, 230022
- Werving
- The First Affiliated Hospital of Anhui Medical Unversity
-
Contact:
- Jianlong Wang, MD
- Telefoonnummer: 0086-13681292304
- E-mail: Wjlmll@sina.com
-
-
Anhui
-
Hefei, Anhui, China, 230001
- Werving
- Anhui Provincial Hospital
-
Contact:
- Kangyu Chen, MD
- Telefoonnummer: 0086 18056005099
- E-mail: ustccky@126.com
-
Hoofdonderzoeker:
- Kangyu Chen, MD
-
Onderonderzoeker:
- Chao Gao, MD
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100035
- Werving
- Beijing Jishuitan Hospital
-
Hoofdonderzoeker:
- Wei Liu, MD
-
Contact:
- Qingwei Ji, MD
- Telefoonnummer: 0086 18376642655
- E-mail: jqwl24@163.cou
-
Hoofdonderzoeker:
- Qingwei Ji, MD
-
Beijing, Beijing Municipality, China, 100029
- Werving
- Anzhen Hospital
-
Contact:
- Yuyang Liu, MD
- Telefoonnummer: 0086 010-64456488
- E-mail: liuyy803803@163.com
-
Hoofdonderzoeker:
- Yuyang Liu, MD
-
Beijing, Beijing Municipality, China, 101100
- Nog niet aan het werven
- Beijing Luhe Hospital
-
Contact:
- Guangyao Zhai, MD
- Telefoonnummer: +86 1069543901
- E-mail: drzhaiguangyao@163.com
-
-
Fujian
-
Fuzhou, Fujian, China, 350001
- Werving
- Fujian Medical University Union Hospital
-
Contact:
- Mingfang Ye, MD
- Telefoonnummer: 0086 13960818759
- E-mail: xieheyemingfang@163.com
-
Hoofdonderzoeker:
- Mingfang Ye, MD
-
Onderonderzoeker:
- Zhaoyang Chen, MD
-
-
Gansu
-
Lanzhou, Gansu, China, 730030
- Werving
- The Second Hospital & Clinical Medical School Lanzhou University
-
Contact:
- Feng Bai, MD
- Telefoonnummer: 0086-13609363049
- E-mail: baifeng@medmail.com.cn
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Werving
- Guangdong Provincial People's Hospital
-
Contact:
- Ning Tan, MD
- E-mail: tanning100@126.com
-
Contact:
- Telefoonnummer: 0086-13903073651
- E-mail: tangning100@126.com
-
-
Heilongjiang
-
Daqing, Heilongjiang, China, 163316
- Werving
- Daqing People's Hospital
-
Contact:
- Shu Zhang
- Telefoonnummer: +86-459-6612898
- E-mail: dqsrmyygcp@163.com
-
Harbin, Heilongjiang, China, 150001
- Werving
- The First Affiliated Hospital of Harbin Medical University
-
Contact:
- Lu Fu, MD
- Telefoonnummer: 0086 137 9668 4968
- E-mail: fuluyidayi@163.com
-
Hoofdonderzoeker:
- Lu Fu, MD
-
Hoofdonderzoeker:
- Yongtai Gong, MD
-
-
Hubei
-
Wuhan, Hubei, China, 430071
- Werving
- Zhongnan Hospital of Wuhan University
-
Contact:
- Xiaorong Hu, MD
- Telefoonnummer: 0086 15927681634
- E-mail: huzrzn@whu.edu.cn
-
Hoofdonderzoeker:
- Xiaorong Hu, MD
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Werving
- The Second Xiangya Hospital fo Central South University
-
Contact:
- Xinqun Hu, MD
- Telefoonnummer: 0086-13307313627
- E-mail: huxinqungs@163.com
-
-
Jilin
-
Changchun, Jilin, China, 130033
- Werving
- The First Hospital of Jilin University
-
Hoofdonderzoeker:
- Qian Tong, MD
-
Contact:
- Qian Tong, MD
- Telefoonnummer: 0086 13074337289
- E-mail: tongqian187@aliyun.com
-
-
Liaoning
-
Shenyang, Liaoning, China, 110015
- Werving
- The People's Hospital of Liaoning Province
-
Hoofdonderzoeker:
- Ying Liu, MD
-
Contact:
- Ying Liu, MD
- Telefoonnummer: 0086 13840065379
- E-mail: liuyingwangli@126.com
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710068
- Werving
- Shaanxi Provincial People's Hospital
-
Contact:
- Xiling Shou, MD
- Telefoonnummer: 0086 18966700335
- E-mail: shouxiling@163.com
-
-
Shandong
-
Jinan, Shandong, China
- Werving
- Central Hospital Affiliated to Shandong First Medicial University
-
Contact:
- Guohai Su, MD
- Telefoonnummer: 0086 19953193319
- E-mail: gttstg@163.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200032
- Werving
- Fudan University-Zhongshan Hospital
-
Hoofdonderzoeker:
- Junbo Ge, MD
-
Contact:
- Junbo Ge, MD
- Telefoonnummer: 021-64041990
- E-mail: ge.junbo@zs-hospital.sh.cn
-
Onderonderzoeker:
- Yuxiang Dai, MD
-
Shanghai, Shanghai Municipality, China, 200001
- Werving
- Renji Hospital Shanghai Jiaotong University school of medicine
-
Contact:
- Jun Bu, MD
- Telefoonnummer: 0086 13601958108
- E-mail: pujun310@hotmail.com
-
Hoofdonderzoeker:
- Jun Bu, MD
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Werving
- West China Hospital of Sichuan University
-
Contact:
- Yong He, MD
- Telefoonnummer: 0086 18980602038
- E-mail: zznnyeah@163.com
-
Hoofdonderzoeker:
- Yong He, MD
-
Chengdu, Sichuan, China, 610072
- Werving
- Sichuan Provincial People's Hospital
-
Contact:
- Jianhong Tao, DM
- Telefoonnummer: 86-189 8183 8875
- E-mail: Taojianhong06@medmail.com.cn
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300211
- Werving
- The Second Hospital of Tianjin Medical University
-
Contact:
- Tong Liu, MD
- Telefoonnummer: 0086 13902183163
- E-mail: liutongdoc@126.com
-
Hoofdonderzoeker:
- Tong Liu, MD
-
Tianjin, Tianjin Municipality, China, 300121
- Werving
- Tianjin People's Hospital
-
Hoofdonderzoeker:
- Zhuhua Yao, MD
-
Contact:
- Zhuhua Yao, MD
- Telefoonnummer: 0086 13902199877
- E-mail: tjyzhpci@163.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310006
- Werving
- Zhejiang Provincial People's Hospital
-
Contact:
- Lihong Wang, MD
- Telefoonnummer: 0086-13666690598
- E-mail: wlhhz@hotmail.com
-
Suzhou, Zhejiang, China, 215006
- Werving
- The First Affiliated Hospital of Soochow University
-
Contact:
- Tingbo Jiang, MD
- Telefoonnummer: 0086-18906201122
- E-mail: jiangtingbo6797@163.com
-
Wenzhou, Zhejiang, China, 325000
- Werving
- The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU
-
Contact:
- lianpin Wu, MD
- E-mail: 198019@wzhealth.com
-
-
-
-
Alabama
-
Huntsville, Alabama, Verenigde Staten, 35801-4312
- Werving
- Heart Center Research, LLC
-
Contact:
- Walter Haught, MD
- Telefoonnummer: 256-519-8472
- E-mail: hhaught@theheartcenter.md
-
-
California
-
Covina, California, Verenigde Staten, 91740
- Nog niet aan het werven
- Thrive Clinical Research Group, LLC
-
Contact:
- Sami Hayek
- Telefoonnummer: 818-280-4220
- E-mail: samihayek82@hotmail.com
-
Contact:
- E-mail: shayek@foothillcardiology.com
-
Lincoln, California, Verenigde Staten, 95648
- Nog niet aan het werven
- Clinical Trials Research
-
Contact:
- Jeffrey Wayne, MD
- Telefoonnummer: 916-434-8230
- E-mail: jwaynemd@ctrsites.com
-
Los Alamitos, California, Verenigde Staten, 90720
- Nog niet aan het werven
- University of California Irvine Medical Center - Cardiovascular Center
-
Contact:
- Arnold Seto
- Telefoonnummer: 562-598-3200
- E-mail: arnold.seto@va.gov
-
Stanford, California, Verenigde Staten, 94305-2200
- Nog niet aan het werven
- Stanford Health Care General Cardiology
-
Contact:
- Fahim Abbasi, MD
- Telefoonnummer: 650-723-6459
- E-mail: fahim@stanford.edu
-
Torrance, California, Verenigde Staten, 90502-2006
- Werving
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
Contact:
- Matthew Budoff, MD
- Telefoonnummer: 310-222-3641
- E-mail: mbudoff@lundquist.org
-
-
Florida
-
Boca Raton, Florida, Verenigde Staten, 33434
- Nog niet aan het werven
- Flourish Research - Boca Raton
-
Contact:
- Richard Goldman
- Telefoonnummer: 561-756-8206
- E-mail: rgoldman@flourishresearch.com
-
Hialeah, Florida, Verenigde Staten, 33016-1895
- Werving
- New Generation of Medical Research, LLC.
-
Contact:
- Karelia Ruiz
- Telefoonnummer: 305-828-9100
- E-mail: kareliar@ngmresearch.com
-
St. Petersburg, Florida, Verenigde Staten, 33709
- Werving
- HCA Florida Heart Institute
-
Contact:
- Robert Sanchez, MD
- Telefoonnummer: 727-490-2100
- E-mail: robert.sanchez7@hcahealthcare.com
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30303-3049
- Nog niet aan het werven
- Emory Healthcare-Emory Heart & Vascular Center - Executive Park
-
Contact:
- Modele Ogunniyi
- Telefoonnummer: 404-616-4440
- E-mail: modele.ogunniyi@emory.edu
-
-
Idaho
-
Meridian, Idaho, Verenigde Staten, 83642
- Nog niet aan het werven
- St. Luke's Clinic - Idaho Cardiology Associates
-
Contact:
- Brian Nolan
- Telefoonnummer: 208-322-1680
- E-mail: bnolan@slhs.org
-
-
Illinois
-
Springfield, Illinois, Verenigde Staten, 62781
- Nog niet aan het werven
- Southern Illinois University School of Medicine
-
Contact:
- Abdul Hafiz, MD
- Telefoonnummer: 217-545-8000
- E-mail: ahafiz96@siumed.edu
-
-
Kansas
-
Overland Park, Kansas, Verenigde Staten, 66211-1215
- Werving
- Midwest Heart & Vascular Specialists, LLC
-
Contact:
- Stephen Bloom, MD
- Telefoonnummer: 913-253-3000
- E-mail: sbloom@kc.rr.com
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63110-1032
- Werving
- WU School of Medicine - (CAM) - Heart and Vascular Center
-
Contact:
- Farhan Katchi, MD
- Telefoonnummer: 314-362-1291
- E-mail: katchif@wustl.edu
-
-
North Carolina
-
Raleigh, North Carolina, Verenigde Staten, 27607
- Nog niet aan het werven
- NC Heart and Vascular Research, LLC
-
Contact:
- Mohit Pasi
- Telefoonnummer: 919-784-2300
- E-mail: mohit.pasi2@unchealth.unc.edu
-
Winston-Salem, North Carolina, Verenigde Staten, 27104-3520
- Nog niet aan het werven
- Javara Inc. - Wake Forest University Health Sciences
-
Contact:
- Michael Shapiro, MD
- Telefoonnummer: 336-713-7251
- E-mail: owen.spitz@javararesearch.com
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45219
- Nog niet aan het werven
- The Christ Hospital
-
Contact:
- Mark Berlacher, MD
- Telefoonnummer: 513-585-1777
- E-mail: Mark.Berlacher@thechristhospital.com
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73135
- Nog niet aan het werven
- South Oklahoma Heart Research, LLC
-
Contact:
- Naeem Tahirkheli
- Telefoonnummer: 405-628-6865
- E-mail: ntahirkheli@okheart.com
-
-
Pennsylvania
-
Camp Hill, Pennsylvania, Verenigde Staten, 17011
- Werving
- Capital Area Research, LLC - Camp Hill
-
Contact:
- Venkatesh Nadar, MD
- Telefoonnummer: 717-695-8722
- E-mail: VNadar@care-research.com
-
-
Texas
-
Amarillo, Texas, Verenigde Staten, 79106
- Werving
- PharmaTex Research, LLC
-
Contact:
- David Brabham
- Telefoonnummer: 806-355-2581
- E-mail: dgbrabham@hotmail.com
-
Carrollton, Texas, Verenigde Staten, 75010
- Nog niet aan het werven
- Pulse Care Heart and Vascular
-
Contact:
- Kiran Kumar Mangalpally
- Telefoonnummer: 214-407-8640
- E-mail: trials@stryderesearch.com
-
Tomball, Texas, Verenigde Staten, 77375
- Nog niet aan het werven
- DM Clinical Research - Dallas
-
Contact:
- Mustafa Mandviwala
- Telefoonnummer: 346-550-9559
- E-mail: drmandviwala.ns@dmclinical.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Fully understands the purposes, features, and methods of the study and the possible adverse reactions, and is voluntarily willing to participate in the study, and signs the informed consent form (ICF) before performing any study-specific assessment.
- Male or female participants between 18 and 80 years (inclusive, at the time of signing the ICF).
- Participants must satisfy either of the following criteria:
1) Have clinically evident atherosclerotic CV disease (ASCVD) 2) Meet at least two of the following criteria at screening/baseline, as evidenced by:
-
A history of Type 2 diabetes requiring treatment with medication,
-
Aged > 55 years (women) or > 50 years (men),
-
2 or more of the following atherosclerosis risk factors:
-
Current cigarette smoker
-
Hypertension
-
Estimated glomerular filtration rate (eGFR) 45 to 60 ml/min/1.73m2
4. Known coronary atherosclerosis as evidenced through coronary angiography or CCTA. The following criteria must be met on the core lab CCTA interpretation for the patient to be enrolled: at least one epicardial coronary artery with a lumen stenosis of 25% to 69%, total coronary NCPV is at least 75 mm3, Detectable low-attenuation composition in one or more individual plaques.
5. Female participants must be non-pregnant and non-lactating
6. Willing and able to comply with the requirements of protocol to the best of the participant's and investigator's knowledge.
-
Exclusion Criteria:
- Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.
- Previously received YN001.
- Any type of vaccination within 4 weeks prior to randomization, or any planned vaccination during the study treatment period
- Contraindication for CCTA
- 3 major epicardial coronary arteries with ≥ 70% or left main ≥50% stenosis.
- Acute MI that occurred within 4 weeks prior to randomization.
- PCI performed within 2 weeks prior to randomization or PCI is required or planned during study treatment based on clinical indication for revascularization.
- Clinically evident stroke or transient ischemic attack (TIA) within 6 months prior to randomization.
- Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months.
- Prior coronary artery bypass graft (CABG), aortic root surgery with coronary reimplantation, left ventricular assist device (LVAD) placement, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or heart transplantation, or a plan to undergo these procedures (CABG, aortic root surgery with coronary reimplantation, LVAD placement, SAVR, TAVR, or heart transplantation) during the study.
- New York Heart Association class III or IV or last known left ventricular ejection fraction (LVEF) was <40%.
- Carotid endarterectomy or stenting, peripheral arterial revascularization, or abdominal aortic aneurysm repair within 4 weeks prior to randomization.
- History of myopathy or myositis, or susceptibility to myopathy/rhabdomyolysis (e.g., family history of hereditary myopathy, etc.).
- History of severe myalgia attributed to statin therapy or other significant concern about statin side effects.
- Known gastrointestinal ulcers, inflammatory bowel disease, or gastrointestinal/rectal bleeding within 6 months prior to randomization.
- Evidence of unresolved major diseases 2 weeks prior to randomization or planned major surgery during the study that, in the investigator's judgement, may interfere with the investigational product administration or trial assessments.
- Presenting with history of malignancy (except in participants who have been disease-free >5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).
- Presence of any type of autoimmune disease.
- Allergy to multiple foods or drugs or known sensitivity to any components to be administered during dosing.
- Life expectancy is less than 1 year.
- Systolic blood pressure of ≥ 160 mmHg at final screening despite antihypertensive therapy.
- Triglycerides ≥ 400 mg/dL (4.5 mmol/L) at final screening.
- LDL-C > 100 mg/dL (2.6 mmol/L) at final screening.
- Active liver disease or hepatic dysfunction defined by any of alanine aminotransaminase (ALT), aspartate aminotransferase (AST), > 3 times upper limit of normal (ULN), or total bilirubin > 2 times ULN at final screening.
- Presence of renal dysfunction, defined by eGFR < 45 ml/min/1.73m2.
- Untreated or inadequately treated hypothyroidism.
- Poorly controlled Type 2 diabetes mellitus.
- A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).
- Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the participant to participate in this study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Dose 1 YN001/Placebo 40mg
Dose 1 YN001/Placobo 40mg will be administrated intravenously weekly |
Dose 1 YN001/Placebo 40mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
|
Experimenteel: Dose 2 YN001/Placebo 20mg
Dose 2 YN001/Placebo 20mg will be administrated intravenously weekly |
YN001/Placebo 20mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
|
Placebo-vergelijker: Dose 3 YN001/Placebo 0mg
Dose 3 YN001/Placebo 0mg will be administrated intravenously weekly |
YN001/Placebo 0mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Relative change from baseline in coronary NCPV at Week 13
Tijdsspanne: Baseline to Week 13
|
Relative change in coronary NCPV from baseline to Week 13 as determined by coronary computed tomography angiography (CCTA) |
Baseline to Week 13
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 13
Tijdsspanne: From baseline to Week 13
|
Absolute change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound. |
From baseline to Week 13
|
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9
Tijdsspanne: From baseline to Week 9
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9 |
From baseline to Week 9
|
|
Relative change from baseline in carotid intima-media thickness (IMT) at Week 13
Tijdsspanne: From baseline to Week 13
|
Relative change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound |
From baseline to Week 13
|
|
Relative change in the maximum thickness and area of carotid plaque at Week 9, and Week 13
Tijdsspanne: From baseline to Week 9 and Week 13
|
Relative change in the maximum thickness and area of carotid plaque from baseline to Week 9, and Week 13 as determined by carotid ultrasound |
From baseline to Week 9 and Week 13
|
|
Relative change in coronary Percent Atheroma Volume (PAV) at Week 13
Tijdsspanne: From baseline to Week 13
|
Relative change in coronary Percent Atheroma Volume (PAV) from baseline to Week 13 as determined by CCTA |
From baseline to Week 13
|
|
Relative change in coronary Low Attenuation Plaque Volume(LAPV) at Week 13
Tijdsspanne: From baseline to week 13
|
Relative change in coronary LAPV from baseline to Week 13 as determined by CCTA. |
From baseline to week 13
|
|
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline at 48 week
Tijdsspanne: From baseline to week 48
|
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline to Week 48 as determined by CCTA |
From baseline to week 48
|
|
Absolute change in coronary NCPV at week 13 and week 48
Tijdsspanne: From baseline to week 13 and week 48
|
Absolute change in coronary NCPV from baseline to Week 13 and Week 48 as determined by CCTA |
From baseline to week 13 and week 48
|
|
Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)
Tijdsspanne: From randomization to Week 96
|
Time to the first occurrence of the MACE, composite of CV death, myocardial infarction (MI), ischemic stroke, urgent coronary revascularization, or hospitalization for unstable angina |
From randomization to Week 96
|
|
The safety profile of YN001
Tijdsspanne: From baseline to Week 13
|
Incidence of treatment emergent adverse event (TEAE)/serious adverse event (SAE)/adverse event of special interest (AESI) |
From baseline to Week 13
|
|
Immunogenicity (ADA) analysis
Tijdsspanne: From baseline to Week 13
|
Incidence of anti-drug antibodies (ADA) formation |
From baseline to Week 13
|
|
Immunogenicity (APA) analysis
Tijdsspanne: From baseline to Week 17
|
Incidence of anti-PEG antibodies (APA) formation |
From baseline to Week 17
|
|
YN001 concentrations analysis in plasma
Tijdsspanne: From baseline to Week 13
|
Sparse blood samples will be collected, and these concentrations are intended to be pooled with other studies to develop/update pharmacometric models |
From baseline to Week 13
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie directeur: Ying Chen, PhD, Beijing Inno Medicine Co., Ltd.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- YN001-203
- IND 157167 (Register-ID: Beijing Inno Medicine Co., Ltd.)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .